• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 17, 2017

View Archived Issues

WashU early AD initiative could yield broader clues; trial adds new candidate

If intervening ahead of symptoms in Alzheimer's disease (AD) works in people with gene mutations that predispose them to getting sick at a younger age, then it will probably work in the rest of the population, principal investigator Randall Bateman theorized to BioWorld Today, and his team at Washington University (WashU) – testing drugs provided by big pharma – hopes to prove as much. Read More

Delays and trolls, data and diversity: That's a wrap for JPM 2017

SAN FRANCISCO – The J.P. Morgan Healthcare Conference – and concurrent conferences and one-on-one meetings – is almost a study in sensory overload, from the crowded hallways at the Westin St. Francis to the speed-dating-style one-on-one meetings to the host of company presentations that probably left attendees dreaming in PowerPoint. Read More

BIA: Rare disease drugs in U.K. could lose in NHS/NICE proposal

LONDON – A proposal intended to speed market access for companies and get innovative products to patients more quickly has been blasted by the U.K. Bioindustry Association (BIA), which said it could block treatments for very rare diseases. Read More

Dual-action, dual-indication decoy fights tumors, viruses

Inhibiting the Axl kinase could have applications in both antitumor and antiviral therapy, separate papers published over the past few weeks have reported. In the Jan. 10, 2017, issue of Cell Reports, a team from the French INSERM Institute showed that Axl receptor activity both enabled Zika virus entry into cells and modulated innate immune responses. Read More

FDA orphan status to help speed Yisheng's PIKA rabies vaccine

HONG KONG – Beijing-based Yisheng Biopharma Co. Ltd. said its PIKA rabies vaccine, which uses Toll-like receptor-3 (TLR-3) activation technology, has received the designation, which the company sees as a great push to bring the vaccine to market. Read More

Holiday Notice

BioWorld's offices were closed Monday, Jan. 16, in observance of the Martin Luther King Day holiday in the U.S. Read More

Financings

Emergent Biosolutions Inc., of Gaithersburg, Md., paid its newly launched oncology and hematology-focused spin-off, Aptevo Therapeutics Inc., of Seattle, $20 million, raising its total contributions to fund the new company's operations to $65 million. Read More

Other news to note

Braeburn Pharmaceuticals Inc., of Princeton, N.J., reported that the Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System code, or permanent J-code, for Probuphine, its six-month buprenorphine implant for the maintenance treatment of opioid addiction. Read More

Appointments and advancements

Dermira Inc., of Menlo Park, Calif., named Lori Lyons-Williams chief commercial officer. Read More

In the clinic

Obseva SA, of Plan-les-Ouates, Switzerland, completed a phase I single and multiple ascending-dose study of OBE022, its once-daily, oral and selective prostaglandin F2alpha, or PGF2alpha, receptor antagonist candidate for the treatment of preterm labor in weeks 24 to 34 of pregnancy. Read More

Bench Press: BioWorld looks at translational medicine

Tumor cells could induce autophagy in neighboring cells of the microenvironment and use resulting macromolecules for their own nutritional gains, and early stage tumors were dependent on microenvironmental autophagy for their growth. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe